Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children
Article first published online: 4 NOV 2007
© 2007 Wiley Periodicals, Inc.
Volume 12, Issue 6, pages 640–642, September 2008
How to Cite
Pape, L., Ahlenstiel, T., Kreuzer, M. and Ehrich, J. H. H. (2008), Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children. Pediatric Transplantation, 12: 640–642. doi: 10.1111/j.1399-3046.2007.00831.x
- Issue published online: 6 AUG 2008
- Article first published online: 4 NOV 2007
- Accepted for publication 14 September 2007
- kidney transplantation;
- gastrointestinal side effects;
- mycophenolate mofetil
Abstract: It has been shown in adult kidney transplant recipients that a conversion from MMF to EC-MPS significantly reduced the GI related symptom burden. No such study exists on children with GI problems while receiving MMF therapy. Ten paediatric kidney transplant recipients (mean age 14.5 yr, s.d. 4.5) receiving triple immunosuppression (Cyclosporin A or Tacrolimus + MMF + Prednisolone) with severe GI symptoms were converted to an equimolar dose of EC-MPS. The GSRS was completed before and at four wk after the switch, and GFR was determined for a mean period of six months. Values were compared by the paired t-test. Mean GSRS improved significantly after the switch to EC-MPS in all but one patient, from 2.1 (s.d. 0.9) to 1.1 (s.d. 0.6). The differences could be found in all four subscales. Graft function did not change after conversion to EC-MPS. In children with moderate or severe GI symptoms while receiving MMF, conversion to EC-MPS led to significantly reduced GI symptoms.